Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by:
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00095160
First received: November 1, 2004
Last updated: October 6, 2009
Last verified: October 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2006
  Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)